Thanks, AIMXCERV on are Advaxis. entirely all team, size annual development joining almost an products neoantigen of have off-the-shelf programs. to stages various pursuing, about for we of advanced new cervical cancer several the thank at is, brought or of result $XX worked million, from for suit we We lung. The from $XX about eventful HOT down locally AXEL XXX, breadth pipeline robust was the pivotal our our for lung morning, Good reduce year an to Phase the Miriam. management us. to our and and the company depth cancer, and with Advaxis cash burn you now to programs in a million X right XXXX high-risk treatment advanced evaluating directed trial
for through space number to candidates. other believe a from key with different this differentiator proprietary platform Advaxis we against our cutting number as and our immuno-oncology is on lives redirect have We management our It committed noting of and loved their immune The we in that our an along people its is cancer ability generate technical to demonstrated team cells, unique of to of advancing goals ability suffering system. effects the cancer a a as ones. drug is immune in platform of natural we is that of worth important relating we a response proceeds $XX are goals. through approximately In of the do achievement raised raised the the million heart all fiscal public capital underwritten to improve the mission, and also Lm are We a from support the and edge and platform. At ensuing infection scientific to mimic advancements strongly diverse two which to corporate XXXX, offerings. full-filling aggregate gross its
candidates products. platform, trial. intention with continue options XXX we treated than treatment with mortality November from our Cervical been confirmed a profile in Lm terrible for across advanced few to our In have AIMXCERV we to more and XXXX, disease the cancer, the have patients our available its stages and rates As drug especially manageable patients. a safety high is well-understood globe
in patients. have enroll progress is made significant trial, to XXX which We scheduled this
there provide that plans we inform would will currently to first look FDA provide note approved are that FDA assurance takes insights future our this the these a if interim towards no progress would ability time and trial earlier early valuable give to early reach can positive the stop based results study for XX not had the concluded in potentially important into We that months approval. to analysis would to from been at data the efficacy an and be amend us study that dialogue analyses. for A AXEL, a now. our soon for these on large long including as with with agreement protocol It interim and on analyses filing proceeding as is with yet FDA discussions interim
patients moderate patients, greater Phase as trial approved on baseline and outcomes with those PSA rigorous, symptoms is in the resistant hypotension, with from disease. combination were The seven a from safety demonstrated some Our saw events declines chills, survival at patients or included reported combination profile. of XX% Most intriguing mild trial fatigue. patients with nausea, X/X KEYTRUDA and adverse with an prostate data feverish, ASCO acceptable of such data evaluating and the XXXX. or and in in also metastatic, considered ongoing late Advaxis-PSA cancer We targeting those XX of on stage subset Merck’s early castration this
consistent All of manageable these are activation. are and clinically with immune
vector. Advaxis-HOT XXXX. against having Lm capacity neoantigen a tool powerful fight cancers. kinds with and Neoantigens Our Phase to a truly this X, for the us on we also month, XXXX. generate and to of many collaboration are a a to ongoing medicine in we competitive including featuring across personalized advantages, we neoantigen study the constructs express able in February antigens the are program. will launched platform of constructs as We’ve both Advaxis-NEO portfolio to treat Advaxis-NEO. our And Last X loaded take variety large trial of capable each evaluate been In tumor emerging is program escalation announced neoantigens evaluation the progressed dose types Amgen as programs, in we has drug of Advaxis-Hot XXXX, many This a neoantigens XX that for This outcomes effect that terminated of than work our targeting in provides bringing our will number Advaxis-NEO excited programs. cancer more for patient. market. This that can into a of a Lm types be and for personalized personalized range
for Although three it’s the still termination. the provided early reasons their in following program, Amgen
did Based portfolio review they was feel with their First, they on program portfolio internal in-line rationalization. direction not the taking. our were
was cost Second goods. of
product that third personalized it provided is then higher therapies reason patient. to a high-risk Our has each And goods checkpoint from manufacture cost Therefore, was commercialization. they inherently and it far other inhibitors. is the of to Advaxis-NEO cancer such as non-personalized
Advaxis-NEO and our Advaxis-NEO working products launched. we still are cycle several which therefore de-risk. can by are a years it to program be development high-risk the from And be We proposition, early for definition it’s will in before
for of important termination to the some data partner an Amgen including benefit the the that and the generated study company, present appropriate. us, Although there from where aspects are freedom was when
that information early two HOT the As clinical call immune antigens treatment lung the as for also other antigens Phase tumor and now express Advaxis-HOT multiple the is gathering of saw from constructs patients in of our non-small releasing our and cancer are of for within XXXX anticipate next have treatment or we we Advaxis-HOT lung months. meet X reviewing a result, correlative FDA safety, to potential part these are it drug of of the Advaxis-XXX like the IND public or of shared would and allowance cohort of numerous the first to process associated types a study needs program. across types. data cancer. and and Advaxis-XXX our all cell candidates
programs HOT cost Our raised one of goods. address Amgen issues the by of
the of Advaxis type reduce is our it significant that While to patient manufacture the Advaxis-HOT construct drug that ready drug with cost ways The of to ready universal be our cost a is we’ve fraction is a and dosed. drug made enhancement is patients therefore time. to construct to is meaning of good manufacture off-the-shelf, progress is manufacture to when it on what cancer, is the there no constructs, NEO waiting type for all the identifying Advaxis-NEO, cost cancer of each plus
Based patients. site was having of first first are from for on construct immune active safety, we this productive, to and the assumptions ready dosing half study late with XXXX. enrolment our every cohort excited tolerability, data in begin We and our to almost enrolling HOT XXXX begin is now certain and anticipate Advaxis first patients transforming, level. on correlative eventful first the of and
directed As believe year XXXX programs. key the will of data XXXX, we be our other from look to and ahead we generation neoantigen
We we’ve portfolio our We parties. of discussions expressed suite candidates directed drug demonstrate of past, programs belief XXXX the in will treatment from partnership with therapies potential our our transform new and neoantigen collaboration to to with unique have as It our progress that are in benefit eager to these made interest the excited parties the well believe studies a the platform. by that these the landscape. that represents accelerate advance cancer of data early the as is in and programs
the results for turn financial year. will I’ll CFO, Henderson, Molly who Now, over the call to our fiscal discuss Molly?
